Akebia Therapeutics, Inc.
AKBA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $723 | $956 | $452 | $416 |
| - Cash | $166 | $137 | $113 | $52 |
| + Debt | $213 | $53 | $54 | $48 |
| Enterprise Value | $770 | $872 | $393 | $411 |
| Revenue | $59 | $62 | $57 | $46 |
| % Growth | -5.9% | 9% | 23.3% | – |
| Gross Profit | $49 | $53 | $50 | $26 |
| % Margin | 83.5% | 84.1% | 86.7% | 56.2% |
| EBITDA | $6 | $7 | $14 | -$7 |
| % Margin | 10.6% | 11.8% | 24.8% | -14.2% |
| Net Income | $1 | $0 | $6 | -$23 |
| % Margin | 0.9% | 0.4% | 10.7% | -49% |
| EPS Diluted | 0.002 | 0.001 | 0.025 | -0.1 |
| % Growth | 122.2% | -96.4% | 125.3% | – |
| Operating Cash Flow | $28 | $22 | -$14 | -$4 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $28 | $22 | -$14 | -$4 |